Evidence map›Paper›PMID 26844469›Full record

ArticleMedicine2016

Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal.

Wenwei Ren, Jingyan Tao, Youdan Wei, Hang Su, Jie Zhang, Ying Xie, Jun Guo, Xiangyang Zhang, Hailing Zhang, Jincai He

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Neurobehavioral and molecular changes in rats exposed to either captagon or counterfeit captagon.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  2. Biochemical Diagnosis in Substance and Non-substance Addiction.Advances in experimental medicine and biology · 2025
    Review
  3. Associations between methamphetamine use disorder andDialogues in clinical neuroscience · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Cognition during active methamphetamine use versus remission.Journal of clinical and experimental neuropsychology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wenwei RenFrom the Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou (WR, JT, HS, JZ, YX, JH); Department of Psychiatry, Hangzhou Seventh People's Hospital, Hangzhou (YW); Sanyang Detoxification Institute, Wenzhou (JG); Beijing HuiLongGuan Hospital, Peking University, Beijing, China (XZ); Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX (XZ); and Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China (HZ).
Jingyan Tao
Youdan Wei
Hang Su
Jie Zhang
Ying Xie
Jun Guo
Xiangyang Zhang
Hailing Zhang
Jincai He
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methamphetamine (METH) is a widely abused illegal psychostimulant, which is confirmed to be neurotoxic and of great damage to human. Studies on the role of brain-derived neurotrophic factor (BDNF) in human METH addicts are limited and inconsistent. The purposes of this study are to compare the serum BDNF levels between METH addicts and healthy controls during early withdrawal, and explore the changes of serum BDNF levels during the first month after METH withdrawal.179 METH addicts and 90 age- and gender-matched healthy controls were recruited in this study. We measured serum BDNF levels at baseline (both METH addicts and healthy controls) and at 1 month after abstinence of METH (METH addicts only).Serum BDNF levels of METH addicts at baseline were significantly higher than controls (1460.28  ±  490.69 vs 1241.27  ±  335.52  pg/mL; F = 14.51, P < 0.001). The serum BDNF levels of 40 METH addicts were re-examined after 1 month of METH abstinence, which were significantly lower than that at baseline (1363.70  ±  580.59 vs 1621.41  ±  591.07  pg/mL; t = 2.26, P = .03), but showed no differences to the controls (1363.70  ±  580.59 vs 1241.27  ±  335.52  pg/mL; F = 2.29, P = 0.13).Our study demonstrated that serum BDNF levels were higher in METH addicts than controls during early withdrawal, and were time dependent decreased during the first month of abstinence. These findings may provide further evidence that increased serum BDNF levels may be associated with the pathophysiology of METH addiction and withdrawal and may be a protective response against the subsequent METH-induced neurotoxicity. Besides, these findings may also promote the development of medicine in the treatment of METH addiction and withdrawal.

Indexed as

Central Nervous System StimulantsMethamphetamineAdultAmphetamine-Related DisordersBrain-Derived Neurotrophic FactorCase-Control StudiesFemaleHumansMaleSubstance Withdrawal SyndromeTime FactorsBDNF protein, humanBrain-Derived Neurotrophic FactorCentral Nervous System StimulantsMethamphetamine

Identifiers

PMID26844469
PMCPMC4748886
OpenAlexW2322010771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.